Hormones are typically larger molecules (often steroids) produced by endocrine glands that act broadly on multiple tissues with long half-lives. Therapeutic peptides are smaller, shorter-acting signaling molecules with more targeted receptor binding. The two can be complementary — many protocols use both — but they are not interchangeable. Hormones replace what the body has lost the ability to produce; peptides nudge specific signaling pathways toward a defined response.
"Hormone" and "peptide" overlap in biochemistry but diverge in clinical use. Some hormones are technically peptides (insulin, glucagon, oxytocin, growth hormone itself). But in the practical language of clinical medicine, "hormone therapy" usually refers to the major steroid and thyroid hormones (estrogen, progesterone, testosterone, DHEA, cortisol, T3/T4) that are replaced when endogenous production is insufficient. "Peptide therapy" usually refers to the smaller, often more targeted molecules used to nudge specific pathways — sermorelin for growth hormone release, BPC-157 for tissue repair, PT-141 for sexual function, AOD-9604 for lipolysis.
| Property | Hormones (clinical use) | Therapeutic peptides |
|---|---|---|
| Molecule size | Steroid (small), thyroid (small but iodine-containing), or large protein hormones (insulin, GH) | 2-50 amino acid chains |
| Source of action | Replace what endogenous glands no longer produce in sufficient quantity | Nudge specific receptor populations toward a defined response |
| Receptor specificity | Usually broader — estradiol acts at estrogen receptors in many tissues | Often narrower — PT-141 acts at central melanocortin receptors; BPC-157 acts at tissue-repair pathways |
| Duration of effect | Hours to days at physiologic doses | Minutes to hours; some peptides modified for longer half-life |
| Treatment arc | Often longer-term (years to decades for postmenopausal replacement, age-related TRT) | Often shorter-term or cyclical (8-12 week courses for tissue repair; chronic for some, intermittent for others) |
| Monitoring approach | Direct serum measurement (estradiol, testosterone, free testosterone, SHBG, etc.) | Indirect — IGF-1 for GH-axis peptides; symptom and tissue response for others |
| Regulatory status | Most bioidentical hormones are FDA-approved preparations or compounded | Mixed — some FDA-approved, many off-label or compounded |
Hormone therapy operates on the principle of restoration. The body's endogenous production has declined (menopause, age-related testosterone decline, primary hypogonadism, thyroid failure) and exogenous hormone is supplied to restore normal physiologic levels. The lab data answers the question: "Where is this hormone now, and where do we want it?" The dose is titrated to a target.
Hormone protocols often run long arcs — years or decades — because the underlying decline doesn't reverse spontaneously. Discontinuation returns the patient to the deficient state. Hormone therapy is replacement, not stimulation.
Peptide therapy operates on the principle of signaling modulation. The body still has the cellular machinery to produce or respond to the relevant signal; the peptide nudges that machinery toward a specific output. Sermorelin doesn't replace growth hormone — it stimulates the patient's pituitary to release more endogenous growth hormone. BPC-157 doesn't replace anything — it amplifies repair signaling at tissue sites. PT-141 doesn't replace a hormone — it activates central melanocortin receptors to produce a defined sexual response.
Peptide protocols are often shorter or cyclical because the goal is to nudge a system that retains its own function. A patient on BPC-157 for tendon healing typically uses it for 4-8 weeks. A patient on sermorelin for sleep and recovery often takes a 3-6 month course, sometimes longer if the goal is durable improvement. PT-141 is used as-needed.
Many protocols use both hormones and peptides because the two address different layers of the same picture. A perimenopausal woman with low energy, poor sleep, and recovery problems might benefit from estradiol/progesterone replacement (hormones) plus a 3-month course of CJC-1295/ipamorelin (peptide). A man on TRT (hormone) might add BPC-157 (peptide) for a tendon injury or use PT-141 (peptide) for sexual function on date nights. The hormones do their long-arc restoration; the peptides do their targeted signaling. The combination produces better clinical outcomes than either category alone when both are clinically indicated.
What we don't do: stack peptides indiscriminately or use peptides to substitute for hormones that the patient actually needs. The right framework is "what is the clinical problem, and what is the appropriate tool?"
The CLARITY methodology evaluates the patient's full picture — biomarkers, symptoms, goals, contraindications — before recommending any intervention. Hormones and peptides are both tools in that framework. Neither is a default. The decision to use one, both, or neither depends on what the data shows. See the methodology in full.
For hormone-specific FAQs, see the Hormone Therapy FAQ. For peptide-specific molecules, see Sermorelin, BPC-157, CJC-1295/Ipamorelin, PT-141.
Upload it. Our clinical team reads it through the CLARITY framework — free.
Get Your Free Lab Review →One consultation. Your biomarkers map the protocol.
Book Your Consultation